Pressmeddelande

  • Patent detecting how patients respond to folate-based cancer treatment approved in the USA

    GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announces the approval from…

    by
  • Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia

    GOTHENBURG, Sweden, November 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion…

    by
  • Isofol’s board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company

    GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that the board…

    by
  • Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer

    GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion…

    by
  • ISOFOL ANNOUNCES THAT AN ABSTRACT HAS BEEN ACCEPTED FOR PRESENTATION AT THE 2019 ESMO CONGRESS

    GOTHENBURG, Sweden, September 12, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that an abstract…

    by
  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a…

    by
  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a…

    by
  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a…

    by
  • Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from…

    by
  • En ny patentansökan för IRLAB:s läkemedelskandidat IRL752 har publicerats av World Intellectual Property Organization, WIPO

    RLAB meddelade idag att World Intellectual Property Organization, WIPO, har offentliggjort en ny patentansökan för läkemedelskandidaten IRL752. Patentansökan gäller ett…

    by